Overview

Chronic Myelogenous Leukemia Treatment Market is projected to grow with a CAGR of nearly 5.3% over the forecast period 2020 to 2027.

FutureWise Market Research has instantiated a report that provides an intricate analysis of Chronic Myelogenous Leukemia Treatment Market trends that shall affect the overall market growth. Furthermore, it includes detailed information on the graph of profitability, SWOT analysis, market share and regional proliferation of this business. Moreover, the report offers insights on the current stature of prominent market players in the competitive landscape analysis of this market.

According to the research study conducted by FutureWise research analysts, the Chronic Myelogenous Leukemia Treatment Market is anticipated to attain substantial growth by the end of the forecast period. The report explains that this business is predicted to register a noteworthy growth rate over the forecast period. This report provides crucial information pertaining to the total valuation that is presently held by this industry and it also lists the segmentation of the market along with the growth opportunities present across this business vertical.

Major players included in the Chronic Myelogenous Leukemia Treatment Market:
• Bristol-Myers Squibb Co.
• Novartis AG
• Pfizer Inc.
• Takeda Pharmaceutical Co. Ltd.
• Teva Pharmaceutical Industries Ltd.
• Mylan NV
• Merck & Co. Inc.
• F. Hoffmann-La Roche Ltd.
• Boehringer Ingelheim International GmbH
• Sanofi-Aventis
(Note: The list of the major players will be updated with the latest market scenario and trends)

Chronic Myelogenous Leukemia Treatment Market Segmentation:
By Treatment Type
• Targeted therapy
• Chemotherapy
• Biologic therapy
• Others
By Region
• North America
• Europe
• Asia-Pacific
• Latin America
• Middle East and Africa

Competitive Landscape:
• Tier 1 players- established companies in the market with a major market share
• Tier 2 players
• Emerging players which are growing rapidly
• New Entrants

FutureWise Key Takeaways:
• Growth prospects
• SWOT analysis
• Key trends
• Key data-points affecting market growth

Objectives of the Study:
• To provide with an exhaustive analysis on the Chronic Myelogenous Leukemia Treatment Market By Treatment Type and By Region.
• To cater comprehensive information on factors impacting market growth (drivers, restraints, opportunities, and industry-specific restraints)
• To evaluate and forecast micro-markets and the overall market
• To predict the market size, in key regions— North America, Europe, Asia Pacific, Latin America and Middle East and Africa.
• To record and evaluate competitive landscape mapping- product launches, technological advancements, mergers and expansions

Flexible Delivery Model:
• We have a flexible delivery model and you can suggest changes in the scope/table of content as per your requirement
• The customization Mobility Care offered are free of charge with purchase of any license of the report
• You can directly share your requirements/changes to the current table of content to: sales@futurewiseresearch.com

Table of Contents

1. Market Introduction
  1.1 Objectives of the Study
  1.2 Market Definition
  1.3 Market Scope
      1.3.1 Years Considered for the Study
      1.3.2 Market Covered
  1.4 Currency
  1.5 Limitations
  1.6 Stakeholders

2. Research Methodology
   2.1 Research Data
       2.1.1 Secondary Data
             2.1.1.1 Key Data from Secondary Sources
       2.1.2 Primary Data
             2.1.2.1 Key Data from Primary Sources
   2.2 Market Size Estimation
   2.3 Market Breakdown and Data Triangulation
   2.4 Assumptions for the Study  

3. Executive Summary
  3.1 Market Outlook
  3.2 Segment Outlook
  3.3 Competitive Insights

4. Global Chronic Myelogenous Leukemia Treatment Market Variables, Trends & Scope
  4.1. Market Lineage Outlook
  4.2. Penetration and Growth Prospect Mapping
  4.3. Industry Value Chain Analysis
  4.4. Cost Analysis Breakdown
  4.5. Technology Overview
  4.6. Regulatory Framework
       4.6.1. Reimbursement Framework
       4.6.2. Standards and Compliances

5. Market Overview
  5.1. Market Dynamics
       5.1.1. Market Driver Analysis
              5.1.1.1. Increasing focus of Chronic Myelogenous Leukemia Treatment Companies on Brand Protection
              5.1.1.2. Untapped Opportunities in Emerging Regions
       5.1.2. Market Restraint Analysis
              5.1.2.1. High Cost Associated with Implementation of Predictive Analysis
       5.1.3. Industry Challenges
              5.1.3.1. Presence of Ambiguous Regulatory Framework

6. Global Chronic Myelogenous Leukemia Treatment Market Analysis Tools
  6.1. Industry Analysis - Porter’s
       6.1.1. Supplier Power
       6.1.2. Buyer Power
       6.1.3. Substitution Threat
       6.1.4. Threat from New Entrants
       6.1.5. Competitive Rivalry
  6.2. Pestel Analysis
       6.2.1. Political Landscape
       6.2.2. Environmental Landscape
       6.2.3. Social Landscape
       6.2.4. Technology Landscape
       6.2.5. Legal Landscape
  6.3. Major Deals And Strategic Alliances Analysis
       6.3.1. Joint Ventures
       6.3.2. Mergers and Acquisitions
       6.3.3. Licensing and Partnership
       6.3.4. Technology Collaborations
       6.3.5. Strategic Divestments
  6.4. Market Entry Strategies
  6.5. Case Studies

7. Global Chronic Myelogenous Leukemia Treatment Market, By Treatment Type Historical Analysis and Forecast 2020-2027 (USD Million)
  7.1. Targeted therapy
  7.2. Chemotherapy
  7.3. Biologic therapy
  7.4. Others

8. North America Chronic Myelogenous Leukemia Treatment Market Analysis 2015–2019 and Forecast 2020–2027 (USD Million)
  8.1. Introduction
  8.2. Historical Market Size (USD Million) Analysis By Country, 2015-2019
       8.2.1. U.S.A
       8.2.2. Canada
       8.2.3. Mexico
  8.3. Market Size (USD Million) Forecast for North America 2020-2027

9. Latin America Chronic Myelogenous Leukemia Treatment Market Analysis 2015–2019 and Forecast 2020–2027 (USD Million)
   9.1. Introduction
   9.2. Historical Market Size (USD Million) Analysis By Country, 2015-2019
         9.2.1. Brazil
         9.2.2. Venezuela
         9.2.3. Argentina
         9.2.4. Rest of Latin America
   9.3. Market Size (USD Million) Forecast for Latin America 2020-2027

10. Europe Chronic Myelogenous Leukemia Treatment Market Analysis 2015–2019 and Forecast 2020–2027 (USD Million)
   10.1. Introduction
   10.2. Historical Market Size (USD Million) Analysis By Country, 2015-2019
         10.2.1. Germany
         10.2.2. U.K        
         10.2.3. France
         10.2.4. Italy
         10.2.5. Spain
         10.2.6. Russia
         10.2.7. Poland
         10.2.8. Rest of Europe
   10.3. Market Size (USD Million) Forecast for Europe 2020-2027
11. Asia Pacific Chronic Myelogenous Leukemia Treatment Market Analysis 2015–2019 and Forecast 2020–2027 (USD Million)
   11.1. Introduction
   11.2. Historical Market Size (USD Million) Analysis By Country, 2015-2019
         11.2.1. Japan
         11.2.2. China
         11.2.3. India
         11.2.4. Australia and New Zealand
         11.2.5. ASEAN
         11.2.6. Rest of Asia Pacific
   11.3. Market Size (USD Million) Forecast for Asia Pacific 2020-2027  

12. Middle East and Africa Market Analysis 2015–2019 and Forecast 2020–2027 (USD Million)
   12.1. Introduction
   12.2. Historical Market Size (USD Million) Analysis By Country, 2015-2019
         12.2.1. Saudi Arabia
         12.2.2. UAE
         12.2.3. South Africa
         12.2.4. Egypt
   12.3. Market Size (USD Million) Forecast for MEA 2020-2027

13. Market Share Analysis and Competitive Landscape  
   13.1. Global Landscape - Key Players, Revenue and Presence
   13.2. Global Share Analysis - Key Players (Tier 1, Tier 2, Tier 3)
   13.3. Global Emerging Companies
   13.4.  North America - Market Share Analysis and Key Regional Players
   13.5.  Europe - Market Share Analysis and Key Regional Players
   13.6.  Asia Pacific - Market Share Analysis and Key Regional Players
   13.7.  Global Key Player - Growth Matrix

14. Company Profiles (Competition Dashboard, Competitors Deep Dive, Products Offered and Financial Layouts)
   14.1. Bristol-Myers Squibb Co.
         14.1.1. Company Overview
         14.1.2. Product Portfolio
         14.1.3. SWOT Analysis
         14.1.4. Financial Overview
         14.1.5. Strategic Overview
   14.2. Novartis AG
         14.2.1. Company Overview
         14.2.2. Product Portfolio
         14.2.3. SWOT Analysis
         14.2.4. Financial Overview
         14.2.5. Strategic Overview
   14.3. Pfizer Inc.
         14.3.1. Company Overview
         14.3.2. Product Portfolio
         14.3.3. SWOT Analysis
         14.3.4. Financial Overview
         14.3.5. Strategic Overview
   14.4. Takeda Pharmaceutical Co. Ltd.
         14.4.1. Company Overview
         14.4.2. Product Portfolio
         14.4.3. SWOT Analysis
         14.4.4. Financial Overview
         14.4.5. Strategic Overview
   14.5. Teva Pharmaceutical Industries Ltd.
         14.5.1. Company Overview
         14.5.2. Product Portfolio
         14.5.3. SWOT Analysis
         14.5.4. Financial Overview
         14.5.5. Strategic Overview          
   14.6. Mylan NV
         14.6.1. Company Overview
         14.6.2. Product Portfolio
         14.6.3. SWOT Analysis
         14.6.4. Financial Overview
         14.6.5. Strategic Overview      
   14.7. Merck & Co. Inc.
         14.7.1. Company Overview
         14.7.2. Product Portfolio
         14.7.3. SWOT Analysis
         14.7.4. Financial Overview
         14.7.5. Strategic Overview
   14.8. F. Hoffmann-La Roche Ltd.
         14.8.1. Company Overview
         14.8.2. Product Portfolio
         14.8.3. SWOT Analysis
         14.8.4. Financial Overview
         14.8.5. Strategic Overview
   14.9. Boehringer Ingelheim International GmbH
         14.9.1. Company Overview
         14.9.2. Product Portfolio
         14.9.3. SWOT Analysis
         14.9.4. Financial Overview
         14.9.5. Strategic Overview
   14.10. Sanofi-Aventis
         14.10.1. Company Overview
         14.10.2. Product Portfolio
         14.10.3. SWOT Analysis
         14.10.4. Financial Overview
         14.10.5. Strategic Overview

15. Pre and Post COVID-19 Impact
   15.1. Positive influence on the healthcare industry
   15.2. The financial disruption of the manufacturing sector
   15.3. Impact of COVID-19 on emerging companies
   15.4. Significant mandates in the healthcare regulations initiated by administrations
   15.5. The overall economic slowdown of the developing and developed nations

16. FutureWise SME Key Takeaway Points for Client

Tables

Figures